Jacqueline Garcia: Evaluating Navitoclax for Myelofibrosis

Jacqueline S. Garcia, MD, shares results from a phase II study of navitoclax, an investigational disease-modifying therapy for the treatment of myelofibrosis, which appears to reduce symptom burden and splenomegaly.

SHARE